Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Mepolizumab Treatment on the Nasal Microbiome and Local and Systemic Immune Response in Eosinophilic Granulomatosis With Polyangitis (eGPA)

NCT06298448 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT06298448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06298448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Mepolizumab Treatment on the Nasal Microbiome and Local and Systemic Immune Response in Eosinophilic Granulomatosis With Polyangitis (eGPA)
Lead sponsor
University Medical Center Groningen
Phase
Observational
Overall status
Recruiting
Start date
February 14, 2024
Completion date
December 31, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egpa - eosinophilic granulomatosis with polyangiitis